Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 14/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7688229 | 0.90 | MEN1 (0.35) | ADRB3ADRB1ALDH1A1LMNAHPGD | |
| SCHEMBL7686590 | 0.85 | LMNA (0.34) | ADRB3ADRB1ALDH1A1LMNAHPGD | |
| Hydrochloric Acid SCHEMBL7691960 | 0.83 | HTR1A (0.46) | ADRB3ADRB1ADRB2HTR1AKDM4E | |
| SCHEMBL7692118 | 0.83 | AURKA (0.37) | ADRB3ADRB1ALDH1A1LMNAHPGD | |
| SCHEMBL7687331 | 0.81 | AURKA (0.39) | ADRB3ADRB1ALDH1A1LMNAHPGD | |
| SCHEMBL7692452 | 0.81 | ADRB1 (0.34) | ADRB3ADRB1LMNA | |
| SCHEMBL7692587 | 0.81 | ADRB3 (0.38) | ADRB3ADRB1ADRB2ALDH1A1HPGD | |
| SCHEMBL7692585 | 0.81 | ADRB3 (0.38) | ADRB3ADRB1ADRB2ALDH1A1HPGD | |
| SCHEMBL7692514 | 0.80 | ADRB1 (0.39) | ADRB3ADRB1ADRB2HTR1AKDM4E | |
| SCHEMBL7693500 | 0.79 | ALDH1A1 (0.35) | ADRB3ADRB1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002000622-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |